Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer

被引：0
|
作者：
Matti S. Aapro
Stephen Chaplin
Paul Cornes
Sebastian Howe
Hartmut Link
Natalia Koptelova
Andrea Mehl
Mario Di Palma
Bridgette Kanz Schroader
Robert Terkola
机构：
[1] Genolier Cancer Center,Gustave Roussy
[2] Xcenda UK,undefined
[3] Comparative Outcomes Group,undefined
[4] Sandoz International GmbH,undefined
[5] Private Practice Hematology Oncology Kaiserslautern,undefined
[6] Paris-Saclay University,undefined
[7] Xcenda LLC,undefined
[8] a Cencora company,undefined
[9] University Medical Center,undefined
[10] Paracelsus Medical University,undefined
来源：
Supportive Care in Cancer | 2023年 / 31卷
关键词：
Febrile neutropenia; Cost-effectiveness; Filgrastim; Biosimilar; Pegfilgrastim;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] An exploratory comparative effectiveness analysis of febrile neutropenia incidence among patients with cancer receiving granulocyte colony stimulating factors.
    Pawloski, Pamala A.
    Lockhart, Catherine
    Vazquez-Benitez, Gabriela
    Defor, Terese A.
    Mendelsohn, Aaron
    Marshall, James
    Moyneur, Erick
    McDermott, Cara L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 408 - 408
  • [42] The economics of febrile neutropenia: Implications for the use of colony-stimulating factors
    Lyman, GH
    Kuderer, N
    Greene, J
    Balducci, L
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) : 1857 - 1864
  • [43] Colony-stimulating factors for chemotherapy-induced febrile neutropenia
    Mhaskar, Rahul
    Clark, Otavio Augusto Camara
    Lyman, Gary
    Botrel, Tobias Engel Ayer
    Paladini, Luciano Morganti
    Djulbegovic, Benjamin
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (10):
  • [44] COST-EFFECTIVENESS OF GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) IN PRIMARY (PP) AND SECONDARY PROPHYLAXIS (SP) OF FEBRILE NEUTROPENIA (FN) IN PATIENTS WITH STAGES 2 AND 3 BREAST CANCER (BC) UNDERGOING CYTOTOXIC CHEMOTHERAPY IN FRANCE
    Perrier, L.
    Bachelot, T.
    Leon, N.
    Maurel, F.
    Cohen-Nizard, S.
    De Liege, F.
    De Liege, F.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A448 - A448
  • [45] The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia
    Jean Klastersky
    Harry Raftopoulos
    Bernardo Rapoport
    [J]. Supportive Care in Cancer, 2013, 21 : 1793 - 1795
  • [46] The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia
    Klastersky, Jean
    Raftopoulos, Harry
    Rapoport, Bernardo
    [J]. SUPPORTIVE CARE IN CANCER, 2013, 21 (06) : 1793 - 1795
  • [47] Febrile neutropenia primary prophylaxis with granulocyte-colony stimulating factors (G-CSF) in breast cancer
    Younis, T.
    Rayson, D.
    Skedgel, C.
    [J]. CANCER RESEARCH, 2013, 73
  • [48] Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
    Advani, S. H.
    Achreckar, Suvarna
    Thomas, Dennis
    Krishnankutty, Binny
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2010, 31 (03) : 79 - 82
  • [49] Impact of granulocyte colony-stimulating factors on febrile neutropenia risk during early-stage breast cancer treatment
    Ben Abdallah, S. S.
    Letarte, N.
    Messier, C.
    Charpentier, D.
    Yelle, L.
    Younan, R.
    Bestawros, A.
    [J]. CANCER RESEARCH, 2013, 73
  • [50] The cost-effectiveness of primary prophylaxis with granulocyte colony-stimulating factor in docetaxel-containing adjuvant chemotherapy in early breast cancer: The impact of risk of febrile neutropenia and its mortality
    Chan, K. K.
    Trudeau, M. E.
    Eisen, A.
    Verreault, J. L.
    Freedman, C. A.
    Dent, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345